BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 37191843)

  • 1. Overall survival after recurrence in stage I-III colorectal cancer patients in accordance with the recurrence organ site and pattern.
    Sawayama H; Miyamoto Y; Hiyoshi Y; Ogawa K; Kato R; Akiyama T; Kiyozumi Y; Yoshida N; Baba H
    Ann Gastroenterol Surg; 2021 Nov; 5(6):813-822. PubMed ID: 34755013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis.
    Ruff SM; Shannon AH; Pawlik TM
    Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of CRISPR screen in mechanistic studies of tumor development, tumor drug resistance, and tumor immunotherapy.
    Li M; Sun J; Shi G
    Front Cell Dev Biol; 2023; 11():1220376. PubMed ID: 37427373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer.
    Yoshino T; Cervantes A; Bando H; Martinelli E; Oki E; Xu RH; Mulansari NA; Govind Babu K; Lee MA; Tan CK; Cornelio G; Chong DQ; Chen LT; Tanasanvimon S; Prasongsook N; Yeh KH; Chua C; Sacdalan MD; Sow Jenson WJ; Kim ST; Chacko RT; Syaiful RA; Zhang SZ; Curigliano G; Mishima S; Nakamura Y; Ebi H; Sunakawa Y; Takahashi M; Baba E; Peters S; Ishioka C; Pentheroudakis G
    ESMO Open; 2023 Jun; 8(3):101558. PubMed ID: 37236086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201.
    Takahashi S; Ouchi K; Sakamoto Y; Mori T; Shimodaira H; Takahashi M; Ohori H; Kudo C; Takahashi Y; Imai H; Akiyama S; Takahashi M; Suto T; Murakawa Y; Oishi T; Isobe H; Okada Y; Kawai S; Yoshioka T; Sato T; Shindo Y; Sugiyama S; Komine K; Chiba N; Okita A; Yamaguchi T; Ishioka C
    J Gastrointest Oncol; 2023 Apr; 14(2):676-691. PubMed ID: 37201044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [K-ras mutational status and tumour-infiltrating lymphocytes in human colon cancer: state of the art and future perspectives].
    Kocián P; Sedivcová M; Drgáč J; Cerná K; Hoch J; Kodet R; Bartůňková J; Spíšek R; Fialová A
    Rozhl Chir; 2012 Aug; 91(8):427-32. PubMed ID: 23153426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
    Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
    Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of RAS/BRAF Mutation Status on Prognosis and Relapse Pattern in Early Stage Colon Cancers.
    Kunt N; Araz M; Yildirim MS; Findik S; Kocak MZ; Eryilmaz MK; Artac M
    J Gastrointest Cancer; 2023 Dec; 54(4):1316-1321. PubMed ID: 37191843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
    Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
    JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.
    Popovici V; Budinska E; Tejpar S; Weinrich S; Estrella H; Hodgson G; Van Cutsem E; Xie T; Bosman FT; Roth AD; Delorenzi M
    J Clin Oncol; 2012 Apr; 30(12):1288-95. PubMed ID: 22393095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
    Taieb J; Balogoun R; Le Malicot K; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Emile JF; Mulot C; Fratté S; Levaché CB; Saban-Roche L; Thaler J; Petersen LN; Bridgewater J; Perkins G; Lepage C; Van Cutsem E; Zaanan A; Laurent-Puig P;
    Ann Oncol; 2017 Apr; 28(4):824-830. PubMed ID: 28031175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.
    Bruzzi M; Auclin E; Lo Dico R; Voron T; Karoui M; Espin E; Cianchi F; Weitz J; Buggenhout A; Malafosse R; Denimal F; Le Malicot K; Vernerey D; Douard R; Emile JF; Lepage C; Laurent-Puig P; Taieb J
    Ann Surg Oncol; 2019 Oct; 26(11):3561-3567. PubMed ID: 31209667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.
    Domingo E; Camps C; Kaisaki PJ; Parsons MJ; Mouradov D; Pentony MM; Makino S; Palmieri M; Ward RL; Hawkins NJ; Gibbs P; Askautrud H; Oukrif D; Wang H; Wood J; Tomlinson E; Bark Y; Kaur K; Johnstone EC; Palles C; Church DN; Novelli M; Danielsen HE; Sherlock J; Kerr D; Kerr R; Sieber O; Taylor JC; Tomlinson I
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):635-643. PubMed ID: 30042065
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.